Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Surface Oncology stock in Canada | $7.69
Own Surface Oncology shares in just a few minutes.
Surface Oncology is a biotechnology business based in the US. Surface Oncology stocks (SURF.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.12 – a decrease of 12.91% over the previous week. Surface Oncology employs 51 staff and has a trailing 12-month revenue of around $89.2 million.
How to buy Surface Oncology stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: SURF in this case.
- Research Surface Oncology stocks. The platform should provide the latest information available.
- Buy your Surface Oncology stocks. It's that simple.
What's in this guide?
- Can I buy shares in Surface Oncology?
- Has coronavirus impacted Surface Oncology shares?
- Surface Oncology shares summary
- Compare share dealing platforms
- Is Surface Oncology stock a buy or sell?
- Surface Oncology performance over time
- Can I short Surface Oncology shares?
- Are Surface Oncology shares over-valued?
- Surface Oncology's financials
- How volatile are Surface Oncology shares?
- Does Surface Oncology pay a dividend?
- Other common questions
How has Coronavirus impacted Surface Oncology's stock price?
Since the stock market crash in March caused by coronavirus, Surface Oncology's stock price has had significant positive movement.
Its last market close was $7.69, which is 49.93% up on its pre-crash value of $3.85 and 457.25% up on the lowest point reached during the March crash when the stocks fell as low as $1.38.
If you had bought $1,000 worth of Surface Oncology stocks at the start of February 2020, those stocks would have been worth $493.72 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,418.27.
Surface Oncology stock priceUse our graph to track the performance of SURF stocks over time.
Surface Oncology stocks at a glance
|Latest market close||$7.69|
|52-week range||$5.15 - $14.4|
|50-day moving average||$7.026|
|200-day moving average||$8.5175|
|Wall St. target price||$16.4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.529|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Surface Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Surface Oncology price performance over time
|1 month (2021-07-01)||4.20%|
|3 months (2021-04-30)||5.20%|
Is Surface Oncology under- or over-valued?
Valuing Surface Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surface Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surface Oncology's P/E ratio
Surface Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Surface Oncology stocks trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Surface Oncology's EBITDA
Surface Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.3 million.
The EBITDA is a measure of a Surface Oncology's overall financial performance and is widely used to measure a its profitability.
Surface Oncology financials
|Revenue TTM||USD$89.2 million|
|Operating margin TTM||28.82%|
|Gross profit TTM||USD$86.3 million|
|Return on assets TTM||9.29%|
|Return on equity TTM||17.63%|
|Market capitalisation||USD$264.8 million|
TTM: trailing 12 months
How to short and sell Surface Oncology stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "SURF.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 4.8 million Surface Oncology stocks held short by investors – that's known as Surface Oncology's "short interest". This figure is 12.6% up from 4.3 million last month.
There are a few different ways that this level of interest in shorting Surface Oncology stocks can be evaluated.
Surface Oncology's "short interest ratio" (SIR)
Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology stocks currently shorted divided by the average quantity of Surface Oncology stocks traded daily (recently around 1.1 million). Surface Oncology's SIR currently stands at 4.54. In other words for every 100,000 Surface Oncology stocks traded daily on the market, roughly 4540 stocks are currently held short.
However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology stocks, or, against the total number of tradable Surface Oncology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.11% of the outstanding stocks (for every 100,000 Surface Oncology stocks in existence, roughly 110 stocks are currently held short) or 0.1469% of the tradable stocks (for every 100,000 tradable Surface Oncology stocks, roughly 147 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Surface Oncology.
Find out more about how you can short Surface Oncology stock.
Surface Oncology stock dividends
We're not expecting Surface Oncology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Surface Oncology stock price volatility
Over the last 12 months, Surface Oncology's stocks have ranged in value from as little as $5.15 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.8426. This would suggest that Surface Oncology's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Surface Oncology overview
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stocks similar to Surface Oncology
Surface Oncology in the news
First Week of September 17th Options Trading For Surface Oncology
Surface Oncology: A Diverse, But Early Pipeline
ARK Investment Leans Into Biotech and Telecom Holdings
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
How to buy Dole (DOLE) stock in Canada when it goes public
Everything we know about the Dole IPO, plus information on how to buy in.